Growing adoption broadens patient access to innovative technology for two-stage breast reconstruction
PALO ALTO, CA, United States — AirXpanders, Inc. (ASX:AXP) (AirXpanders or Company), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today updated the market on the progress of its commercial roll-out in the United States. AeroForm is now available in more than one hundred (100) medical institutions and health systems, located throughout the country.
AeroForm offers a needle-free alternative for women who choose reconstructive surgery following a mastectomy. AeroForm is activated by a handheld wireless controller that administers small amounts of carbon dioxide (CO2) up to three times a day, to gradually stretch the tissue to prepare for a breast implant. With the push of a button from the wireless controller, a preprogrammed amount of CO2 is delivered in seconds, allowing the patient to continue with her daily activities while preparing for reconstruction. AeroForm was granted de novo clearance by the U.S. Food and Drug Administration (FDA) on December 21, 2016.
For further information please download PDF attached:
Download this document
